Abstract

P-131 Evaluation of predictive factors of toxicity of chemotherapy with FOLFIRINOX in patients treated for pancreatic adenocarcinoma

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Safety and efficacy of modified dose-attenuated FOLFIRINOX chemotherapy in patients over 65 years with advanced pancreatic adenocarcinoma.
Matheus Bongers Alessandretti ... Raphael Brandao Moreira
Journal of Clinical Oncology | VOL. 33
Matheus Bongers Alessandretti, et. al.Matheus Bongers Alessandretti ... Raphael Brandao Moreira
20 Jan 2015
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial
Angela Alistar ...
Lancet Oncology | VOL. 18
Angela Alistar, et. al.Angela Alistar ...
08 May 2017
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
A Orlandi ... A Cassano
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | VOL. 18
A Orlandi, et. al.A Orlandi ... A Cassano
07 Jan 2016
Neoadjuvant gemcitabine, docetaxel, and capecitabine results in comparable surgical outcomes to modified FOLFIRINOX in patients with pancreatic ductal adenocarcinoma who also receive radiation: A single institution experience.
Winston Wong ... Tristan Lee
Journal of Clinical Oncology | VOL. 40
Winston Wong, et. al.Winston Wong ... Tristan Lee
01 Feb 2022
View more papers

More From: Annals of oncology : official journal of the European Society for Medical Oncology

Paper Title
Journal
Date
Author
Challenging immune exhaustion in early recurrent triple-negative breast cancer: pitfalls and hopes
P Tarantino ... S M Tolaney
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 35
P Tarantino, et. al.P Tarantino ... S M Tolaney
01 Jul 2024
Proofreading the way: immune checkpoint inhibitors in polymerase ε/polymerase δ (POLE/POLD1)-altered colorectal cancer
M Cecchini ... R Sundar
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 35
M Cecchini, et. al.M Cecchini ... R Sundar
01 Jul 2024
Table of Contents
-
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 35
--
01 Jul 2024
Editorial Board
-
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 35
--
01 Jul 2024
View more papers